Shepherd Financial Partners LLC Has $657,000 Position in Pfizer Inc. (NYSE:PFE)

Shepherd Financial Partners LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,718 shares of the biopharmaceutical company’s stock after selling 3,284 shares during the period. Shepherd Financial Partners LLC’s holdings in Pfizer were worth $657,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of PFE. LGT Group Foundation grew its stake in Pfizer by 2.5% in the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after purchasing an additional 18,274 shares in the last quarter. Creative Planning grew its stake in shares of Pfizer by 17.1% in the third quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock valued at $52,692,000 after buying an additional 266,167 shares in the last quarter. ORG Partners LLC increased its holdings in Pfizer by 1,729.9% during the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after buying an additional 44,458 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in Pfizer by 10.3% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 256,460 shares of the biopharmaceutical company’s stock valued at $7,422,000 after acquiring an additional 23,928 shares during the last quarter. Finally, Everett Harris & Co. CA grew its position in shares of Pfizer by 21.7% in the 3rd quarter. Everett Harris & Co. CA now owns 218,344 shares of the biopharmaceutical company’s stock valued at $6,319,000 after acquiring an additional 38,870 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PFE. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Citigroup assumed coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. Wells Fargo & Company boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Price Performance

Pfizer stock traded up $0.06 during mid-day trading on Friday, reaching $28.36. The company had a trading volume of 12,827,420 shares, compared to its average volume of 37,103,188. The business has a fifty day simple moving average of $29.05 and a 200 day simple moving average of $28.56. The company has a market cap of $160.71 billion, a P/E ratio of 38.38, a P/E/G ratio of 0.90 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The business’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period last year, the company earned ($0.17) earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.92%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Insider Activity

In other news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.